Lilly's Keflex patent
Executive Summary
Lilly plans to appeal a New Jersey Federal Court decision that found scope of Lilly's Keflex (cephalexin) patent was not as broad as the company maintained. Lilly filed a patent infringement suit against Vitarine in February. Lilly says the patent in litigation relates to a dense crystalline form of cephalexin, and maintains that the patent does not expire until 1989. The patent covering the cephalexin molecule expired in April.
Lilly plans to appeal a New Jersey Federal Court decision that
found scope of Lilly's Keflex (cephalexin) patent was not as broad
as the company maintained. Lilly filed a patent infringement suit
against Vitarine in February. Lilly says the patent in litigation
relates to a dense crystalline form of cephalexin, and maintains
that the patent does not expire until 1989. The patent covering the
cephalexin molecule expired in April. |